Covid19, SARS-CoV 2 Infection
Conditions
Keywords
COVID-19, Anti-septic, Carrageenan, Nasal spray, Povidone-Iodine(PVP-I), Gargle, Mouthwash
Brief summary
The goal of this study is to recruit confirmed Covid-19 patients, to evaluate whether the topical anti-septic can improve clinical outcome in early Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection. During the global pandemic period, an effective and highly available method once be identified, it will reduce the risk of disease transmission and lower the medical burden.
Detailed description
Oral and nasal disinfection, a simple method with the application of commonly used antiseptic agents is frequently performed in the otolaryngology and dental practice. The ability to deactivate viral particles with a good safety profile may be an important benefit in the control of viral proliferation and shedding. Actually, multiple anti-septic agents demonstrated virucidal properties against SARS-CoV-2 in several in vitro studies. Among these, Povidone-Iodine (PVP-I), common usage in otolaryngology operation and topical therapy, showed high virucidal properties (0.45% PVP-I, throat spray, 4-log drop in viral load) and of great safety. There is also evidence that topical usage of saline can decrease the severity of upper respiratory tract infection. In addition, carrageenan, a sulphated polysaccharide purified from red marine algae, had shown efficacy in inhibiting multiple viruses, including in vitro studies of SARS-CoV-2. Some randomized controlled trials had also shown their abilities in improving patients' symptoms with a good safety profile. Multiple international organizations are conducting relating randomized clinical trials to evaluate whether the topical anti-septic improves clinical outcomes after early SARS-CoV-2 infection. The added value of topical antiseptic agents may be beneficial in improving symptoms, reducing viral load and alleviating the rate of disease progression. Due to relatively low risk, well-toleration to the general population, and highly available characteristics, the potential benefits of these agents deserve more attention. The goal of this study is to investigate the changes in clinical symptoms and sequential laboratory data in confirmed COVID-19 adult patients at the early disease stage. By applying topical anti-septic which is frequently used in otolaryngology procedures, the investigators will evaluate the impact of this intervention on the symptoms, viral load and the rate of disease progression. During the global pandemic period, an effective and highly available method once be identified, it will reduce the risk of disease transmission and lower the medical burden.
Interventions
DRUGCarrageenan nasal spray and 1% PVP- mouthwash and gargle
Day1 to Day7 1. Intranasal spray 3 times/day, 2\ 3 spray/nostril/per time 2. Oral gargling 3 times/day, 15cc/per time
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age older than 20 years of age 2. admission with a confirmed positive test for SARS-CoV-2 infection by reverse transcription polymerase chain reaction (RT- PCR) 3. disease onset (start of COVID-19 symptom and PCR test) for ≤ 120 hours 4. available informed consent of this study. 5. Full COVID-19 vaccination(at least after 2nd dose of TFDA-approved vaccine 14 days)
Exclusion criteria
1. receiving oxygen supply before intervention 2. known intolerance/allergy to the study drugs 3. pregnancy 4. sinus/oral operation within 30 days of the beginning of the study 5. using intranasal medication before randomization 6. no available informed consent 7. inability to self-care or reply to questionnaire
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day 8 | 7 days | the mean change of viral titers of COVID-19 between Day 1 and Day 8 by RT-PCR test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| frequency of adverse effects of interest after anti-septic | 10 days | including nasal discomfort, sneezing, epistaxis, headache and otalgia |
| number of days in an ICU | up to 14 days | number of days in an ICU |
| number of days Non Invasive Ventilation (NIV) was required during hospitalization | up to 14 days | NIV usage during hospitalization |
| symptoms related to COVID-19 | 10 days | including cough, fatigue, shortness of breath, loss of smell, hoarseness, chest pain, abdominal pain, diarrhea, headache, sore throat, muscle pain, etc and Quality of Life using the validated SinoNasal Outcome Tool-22 (SNOT-22, total score range 0-110, higher scores represent worse symptoms) |
| length of hospitalization | up to 14 days | length of hospitalization |
| days of discharge | up to 30 days | free from quarantine |
| mortality rates | up to 30 days | mortality rates |
Countries
Taiwan
Outcome results
None listed